SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as the community celebrates the recovery of its ticker symbol and continues to push for broader visibility while emphasizing their commitment to an organic, long-term project. Investors are actively discussing the potential for a forthcoming chart listing and rallying around a narrative of collective building to differentiate themselves from short-term memecoin scams.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is seeing significant momentum driven by CEO Andy Jassys confirmation of a massive AI infrastructure spend and a $20 billion revenue run rate for its custom silicon business, sparking optimism that it is successfully pivoting toward long-term AI dominance. Community sentiment is increasingly bullish, with traders actively discussing its strategic partnerships with Anthropic and the potential for a major valuation re-rating as AWS scales.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following a significant multi-year cloud infrastructure deal with Anthropic to support its Claude models, signaling sustained demand for high-performance AI compute. While the partnership has fueled bullish sentiment around its expanding roster of major AI clients, traders are simultaneously debating the impact of the company's concurrent upsized debt offering and broader market volatility.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit is currently trending as investors debate whether the recent sharp sell-off is a fundamental breakdown driven by AI-related disruption or a massive overreaction to bearish sentiment. While community sentiment is heavily divided, many are treating the pullback as a long-term opportunity to buy a profitable, high-margin leader at valuation levels not seen in years, pointing to share buyback acceleration and a strong competitive moat as key catalysts for a potential reversal.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

Investors are actively flocking to UVIX as a hedge against rising geopolitical tensions in the Middle East and concerns over oil supply disruptions following the closure of the Strait of Hormuz. The community is heavily debating whether the current market stability is a temporary lull driven by political rhetoric or a fragile calm before a significant volatility breakout, fueling intense discussion around potential black swan events.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors focus on its critical role as the gatekeeper of AI infrastructure, buoyed by massive order backlogs and a recent breakthrough in lithography technology that promises a 50% boost in chip output by 2030. While some market participants debate potential valuation stretching, the community remains intensely focused on the company's monopoly on EUV systems as a non-negotiable bottleneck for global semiconductor scaling.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing heightened community discussion as investors weigh its aggressive infrastructure expansion against ongoing concerns regarding potential equity dilution from its sizable at-the-market offering. The stock is currently being closely monitored for a potential breakout as traders look for news on site energizations and new hyperscaler partnerships to confirm its competitive standing within the evolving AI and data center sector.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as investors focus on its pivot to building a domestic heavy rare earth metallization facility designed to replace Chinese-sourced materials in U.S. defense supply chains. The community is actively debating the company's long-term potential as a critical defense contractor against concerns regarding its pre-revenue status and capital structure.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is seeing intense market volatility and increased short interest following a board-level shakeup, with the community actively debating whether the resignation of a key board member signals deeper governance issues or a buying opportunity. Traders are heavily focused on the company's strong fundamentals and upcoming earnings as potential catalysts to trigger a short squeeze against a backdrop of ongoing institutional accumulation.

TOSHI

TOSHI is trending as the community debates its long-term potential as the face of the Base ecosystem, with investors actively discussing accumulation strategies during current market volatility. Sentiment is polarized, as some members express frustration over price performance while others highlight technical indicators like bullish divergences as signs of a potential reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement in April 2025.&nbsp;</li><li>The company added on Wednesday that it is still eligible to earn up to $337.5 million more in additional research, development and commercial milestone-based payments.&nbsp;</li><li>CEO Lucinda Warren said that the company is pleased with the milestone payment as it progresses its lead autoimmune asset, CUE-401, toward the clinic.</li></ul>Shares of Cue Biopharma, Inc. (CUE) is on track to record its best session to date, if gains hold, after the company announced earlier this week that it will receive $7.5 million as milestone payment from an agreement with Boehringer Ingelheim.CUE stock is up 77% at the time of writing.<h2 class="st-heading-2">Cue- Boehringer Ingelheim Deal</h2>Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement in April 2025 &nbsp;to develop and commercialize Cue Biopharma’s CUE-501 product candidate for autoimmune diseases.Under the deal, Cue received an upfront payment of $12 million and is eligible to earn up to about $345 million in research, development and commercial milestone-based payments, as well as royalty payments on net sales.The company now expects a $7.5 million payment in May 2026. Cue Biopharma also said on Wednesday that it is still eligible to earn up to $337.5 million more in additional research, development, and commercial milestone-based payments.CEO Lucinda Warren said that the company is pleased with the milestone payment as it progresses its lead autoimmune asset, CUE-401, toward the clinic. In February, the company said that its preclinical data demonstrated that CUE-401 was well tolerated with no adverse events.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CUE stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user expressed optimism about the rally after a quiet period. “This is starting to get interesting,” they wrote<stembedurl>https://www.stocktwits.com/topstockalerts/message/649975686</stembedurl>Another user highlighted the possibility of additional payments under the deal.<stembedurl>https://www.stocktwits.com/Aburose/message/649968775</stembedurl><a href="https://stocktwits.com/symbol/CUE">CUE stock</a> has fallen 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto">REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cue Biopharma logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CUE Stock On Track For Best Day In History — Why Is Retail Optimistic?

Cue now expects a $7.5 million payment from Boehringer Ingelheim in May 2026.

Equity

Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim

Cue Biopharma stock jumps after $7.5 million milestone from Boehringer Ingelheim, with additional milestone potential and pipeline progress.read more...

Get Ready for the Weekend with One of these Strong Runners

Today’s market action is dominated by a bunch of listings we’ve covered this week, plus a few fresh faces, like Cue Biopharma (NASDAQ:CUE), which is running strong after announcing, on Wednesday, that it will receive $7.5 million preclinical milestone payment for its agreement with Boehringer Ingelheim, while Xiao-I (NASDAQ:AIXI) has been in play since providing an update on its Apple (NASDAQ:AAPL) patent infringement lawsuit. $SKYQ, $KBLB, $UCAR, $ELAB, $CUE, $AIXI, $AAPL, $CREG, $RAYA

Shares of Cue Biopharma (CUE) fell 8% in extended trading hours on Friday after the company announced that its top leader Usman Azam has stepped down as president and CEO, effective March 26.Azam also resigned from his role as a director of the company. Azam was appointed into the role in late-September, replacing former CEO Daniel Passeri, and served merely six months in the role. &nbsp;<h2 class="st-heading-2">New CEO</h2>Lucinda Warden has been appointed interim president and CEO, the company said. Warden served as Cue Biopharma’s chief financial and business officer since Feb. 2026, and previously as Cue Biopharma’s chief business officer from Sept. 2024 until Feb. 2026.Prior to working with Cue, Warden was employed with Johnson &amp; Johnson and Janssen Biologics.<h2 class="st-heading-2">Cue Pipeline</h2>Boston, Massachusetts-headquartered Cue Biopharma is now looking to progress CUE-401 into clinical trials by the second half of this year. The investigational drug is the company’s lead asset for the treatment of autoimmune and inflammatory diseases. In preclinical studies, CUE-401 was well tolerated with no adverse events observed.In November, Cue also entered into a collaboration and license agreement with ImmunoScape, Pte. Ltd, a biotechnology company, to advance a novel in vivo approach to cell therapy for the treatment of solid tumors.Under the agreement, ImmunoScape will develop a novel Seed-and-Boost immunotherapy that combines Cue Biopharma’s clinically-validated Immuno-STAT T-cell engagers, with ImmunoScape’s proprietary T cell receptors.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CUE stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.<a href="https://stocktwits.com/symbol/CUE">CUE stock</a> has fallen 76% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-nearly-halved-in-past-year-but-wall-street-sees-almost-500-percent-upside/cZ3HgAcRImK">ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CUE Stock Slips As CEO Leaves After Just Six Months In Role

Usman Azam was appointed into the role in late-September, replacing former CEO Daniel Passeri.  

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates

Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.00% and -14.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates

CERVOMED INC (CRVO) delivered earnings and revenue surprises of -23.53% and -69.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of +133.33% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +6.25% and +38.15%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of -32.58% and +24.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.77% and +47.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.09	$0.01	111.11%	BEAT
Q3 '25	-$0.09	-$0.07	25.00%	BEAT
Q2 '25	-$0.13	-$0.09	30.77%	BEAT
Q1 '25	-$0.15	-$0.17	-10.87%	MISSED
Q4 '24	-$0.09	-$0.13	-51.16%	MISSED

CUE
Cue Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest CUE News

CUECue Biopharma Inc